

[0009c] In a third aspect of the present disclosure, there is provided a compound N-(4-((2-acetamidopyridin-4-yl)oxy)-2,5-difluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, or a pharmaceutically acceptable salt, solvate, hydrate or tautomer thereof.

[0009d] In a fourth aspect of the present disclosure, there is provided a compound N-(2,5-difluoro-4-((2-propionamidopyridin-4-yl)oxy)phenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, or a pharmaceutically acceptable salt, solvate, hydrate or tautomer thereof.

[0009e] In a fifth aspect of the present disclosure, there is provided a compound N-(4-((2-(cyclopropanecarboxamido)pyridin-4-yl)oxy)-2,5-difluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, or a pharmaceutically acceptable salt, solvate, hydrate or tautomer thereof.

[0009f] In a sixth aspect of the present disclosure, there is provided a compound N-(4-((2-(3,3-dimethylureido)pyridin-4-yl)oxy)-2,5-difluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, or a pharmaceutically acceptable salt, solvate, hydrate or tautomer thereof.

[0009g] In a seventh aspect of the present disclosure, there is provided a compound N-(2,5-difluoro-4-((2-isobutyramidopyridin-4-yl)oxy)phenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, or a pharmaceutically acceptable salt, solvate, hydrate or tautomer thereof.

~~**[0009h]** In an eighth aspect of the present disclosure, there is provided a use of a disclosed compound for the manufacture of a medicament for treating mammalian disease wherein the disease etiology or progression is at least partially mediated by a kinase activity, wherein the kinase is a wildtype form, a mutant oncogenic form, an aberrant fusion protein form or a polymorph, wherein the medicament is to be administered to a mammal in need thereof.~~

[0009ih] In an eighth ~~ninth~~ aspect of the present disclosure, there is provided a pharmaceutical composition, comprising a disclosed compound and a pharmaceutically acceptable carrier.

[0009ji] In a ~~tenth~~ ninth aspect of the present disclosure, there is provided a use of a disclosed compound for the manufacture of a medicament for treating ~~cancer~~, gastrointestinal stromal tumors, hyperproliferative diseases, metabolic diseases, neurodegenerative diseases, or diseases characterized

by angiogenesis, such as solid tumors, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, renal cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including retinopathies, diabetic retinopathy, age-related macular degeneration, or hypereosinophilic syndrome, wherein the medicament is to be administered to a patient in need thereof.

[0009] In an ~~eleventh~~ tenth aspect of the present disclosure, there is provided a use of a disclosed compound for the manufacture of a medicament for treating ciliopathies or polycystic kidney disease, wherein the medicament is to be administered to a patient in need thereof.

[0010] Specifically, pyridone amide compounds of **Formula I** are disclosed which find utility in the treatment of diseases as described above.

19. The compound N-(4-((2-(cyclopropanecarboxamido)pyridin-4-yl)oxy)-2,5-difluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, or a pharmaceutically acceptable salt, solvate, hydrate or tautomer thereof.
20. The compound N-(4-((2-(3,3-dimethylureido)pyridin-4-yl)oxy)-2,5-difluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, or a pharmaceutically acceptable salt, solvate, hydrate or tautomer thereof.
21. The compound N-(2,5-difluoro-4-((2-isobutyramidopyridin-4-yl)oxy)phenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, or a pharmaceutically acceptable salt, solvate, hydrate or tautomer thereof.

~~22. Use of a compound of claim 1 for the manufacture of a medicament for treating mammalian disease wherein the disease etiology or progression is at least partially mediated by a kinase activity, wherein the kinase is a wildtype form, a mutant oncogenic form, an aberrant fusion protein form or a polymorph, wherein the medicament is to be administered to a mammal in need thereof.~~

~~23. The use of claim 22, wherein the disease etiology or progression is at least partially mediated by the kinase activity of c-MET, mutant oncogenic forms, aberrant fusion proteins, or polymorphs thereof.~~

~~2422.~~ A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

~~2523.~~ The composition of claim ~~2422~~, further comprising an additive selected from adjuvants, excipients, diluents, or stabilizers.

~~2624.~~ Use of a compound of claim 1 for the manufacture of a medicament for treating ~~cancer,~~ gastrointestinal stromal tumors, hyperproliferative diseases, metabolic diseases, neurodegenerative diseases, or diseases characterized by angiogenesis, such as solid tumors, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, renal cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases.

leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, ~~hypereosinophilic syndrome, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including~~ retinopathies, diabetic retinopathy, age-related macular degeneration, or hypereosinophilic syndrome, ~~wherein the medicament is to be administered to a patient in need thereof.~~

~~2725.~~ Use of a compound of claim 1 for the manufacture of a medicament for treating ciliopathies or polycystic kidney disease, ~~wherein the medicament is to be administered to a patient in need thereof.~~

~~2826.~~ The use of claims ~~22, 23, 26 or 2724~~ or 25, wherein the medicament is to be administered orally, parenterally, by inhalation, or subcutaneously.